NRXP NRx Pharmaceuticals, Inc.
Price Chart
Executive Summary
NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ketamine (NRX-100) demonstrated significantly higher remission and response rates vs. intranasal esketamine in a real-world study of over 10,000 patients. The data supports NRx's NDA filing for NRX-100 in suicidal depression, with the FDA emphasizing real-world evidence via a recent Executive Order and Congressional language.
Actionable Insight
The real-world evidence significantly strengthens NRx's NDA filing for NRX-100, especially with regulatory tailwinds from the White House and Congress. Monitor for FDA acceptance of the NDA and any Type C meeting outcomes. The stock has historically shown strong positive drift on catalyst news (avg T+20 +35% on prior bullish calls).
Key Facts
- IV ketamine patients showed 50% higher odds of remission (OR 1.51; P<.001) and 22% higher odds of response (OR 1.22; P<.003) vs. intranasal esketamine.
- Study analyzed 8,224 IV ketamine and 1,830 intranasal esketamine patients from 800 community clinics.
- 34% of IV ketamine patients achieved remission vs. 26% for esketamine; 63% vs. 58% response rate.
- NRx has filed an NDA for NRX-100 (IV ketamine) with a National Priority Voucher Program application for suicidal depression.
- White House Executive Order and House Appropriations language support use of real-world evidence for depression drug approvals.
- NRx has Fast Track Designation for NRX-100 in suicidal depression and Breakthrough Therapy Designation for NRX-101 in suicidal bipolar depression.
Financial Impact
No financial figures disclosed; potential market opportunity for NRX-100 in suicidal depression (large unmet need) but no revenue or deal value provided.
Risk Factors
- Study limitations: non-randomized design, potential unmeasured confounding variables.
- FDA may still require randomized controlled trials for full approval, despite real-world evidence support.
- NRx is a clinical-stage biopharma with no approved products and no disclosed revenue.
- Competition from existing esketamine (Spravato) and other NMDA-targeting therapies.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307371 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
Press Release
| $4.12 awaiting T+1 | awaiting T+1 | — | $3.84 (−6.80%) |
|
Jun 4, 2026
8d ago
|
Press Release
| $4.05 awaiting T+1 | awaiting T+1 | — | $3.84 (+5.19%) |
|
Jun 3, 2026
9d ago
|
Press Release
| $4.05 $4.05 | · 0.00% | ▲ +0.40% | $3.84 (+5.19%) |
|
Jun 2, 2026
10d ago
|
Press Release
| $4.05 $4.05 | · 0.00% | ▲ +0.41% | $3.84 (+5.19%) |
|
May 18, 2026
25d ago
|
Press Release
| $3.12 $3.03 | ▼ −2.73% | ▼ −2.08% | $3.84 (+23.27%) |
|
May 14, 2026
29d ago
|
Press Release
| $3.21 $3.28 | ▲ +2.18% | ▲ +3.41% | $3.84 (+19.63%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $2.09 $2.13 | ▲ +1.91% | ▼ −0.98% | $3.84 (+83.73%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $1.84 $1.85 | ▲ +0.54% | ▲ +2.29% | $3.84 (+108.70%) |
|
Feb 24, 2026
15w ago
|
DEFA14A
| $1.91 $1.93 | ▲ +1.05% | ▲ +1.59% | $3.84 (+101.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access